2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P11119
    CKS peptide 98%
    CKS peptide is a selective substrate peptide for CK1. CKS peptide can used to measure CK1 activity.
    CKS peptide
  • HY-P11124
    MGF24 1611488-66-4
    MGF24 is a modified protease-resistant MGF derivative. MGF24 protects dopaminergic neurons from 6-Hydroxydopamine (6-OHDA) (HY-113028)-induced apoptosis by inducing Heme oxygenase-1 (HO-1). MGF24 activates PKC-ε, which in turn activates Nrf2, up-regulating HO-1. MGF24 has neuroprotective activity and reduces myocardial infarct size in sheep models of myocardial ischemia. MGF24 can be used for neurological diseases like stroke, nerve injury and amyotrophic lateral sclerosis research.
    MGF24
  • HY-P1112A
    Sarafotoxin S6a TFA 98%
    Sarafotoxin S6a TFA , a sarafotoxin analogue, is a endothelin receptor agonist and has an ETA/ETB selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a TFA elicits the pig coronary artery with an EC50 value of 7.5 nM.
    Sarafotoxin S6a TFA
  • HY-P11130
    LQEQ-19 (mouse, rat) 322644-72-4 98%
    LQEQ-19 (mouse, rat) is a VGF derived peptide that exerts neuroprotective effects. LQEQ-19 (mouse, rat) activates the PI3K/Akt and MEK/ERK signaling pathways by promoting phosphorylation of Akt and ERK1/2. LQEQ-19 (mouse, rat) is commonly used in the study of neurological conditions.
    LQEQ-19 (mouse, rat)
  • HY-P11133
    Leukokinin 1 157674-89-0
    Leukokinin 1 is a member of the leucokinin peptide family. Leukokinin 1 operates by binding to and activating specific G-protein-coupled receptors (GPCRs). Leukokinin 1 plays a wide role in the central nervous system (CNS) of molluscs. Leukokinin 1 can be used for research on neurological disease.
    Leukokinin 1
  • HY-P11144
    Inotocin 112667-33-1 98%
    Inotocin is a neuropeptide belonging to the oxytocin/vasopressin family in insects. Inotocin does not participate in water balance regulation. Inotocin may regulate reproductive behavior, especially parental care.
    Inotocin
  • HY-P1117A
    MMK1 TFA 98%
    MMK1 TFA is a potent and selective human formyl peptide receptor like-1 (FPRL-1/FPR2) agonist with EC50s of <2 nM and >10000 nM for FPRL-1 and FPR1, respectively. MMK1 TFA is a potent chemotactic and calcium-mobilizing agonist. MMK1 TFA potently activates phagocytic leukocytes and enhances Pertussis Toxin-sensitive production by human monocytes of proinflammatory cytokines IL-1b and IL-6. MMK1 TFA exerts anxiolytic-like activity.
    MMK1 TFA
  • HY-P11196
    Allatostatin C 1412455-91-4 98%
    Allatostatin C (AstC) is a neuropeptide that suppresses gonadotropin production. Allatostatin C generates oogenesis rhythm by regulating juvenile hormone and vitellogenesis indirectly via insulin signaling. Allatostatin C can be used for neurological research.
    Allatostatin C
  • HY-P11222
    Tat-SERT-15C 2614435-43-5
    Tat-SERT-15C is a peptide. Tat-SERT-15C decreases the SERT-nNOS complex and increases SERT. Tat-SERT-15C reverses chronic unpredictable mild stress-caused depression behaviors.
    Tat-SERT-15C
  • HY-P11226
    TI-16 659739-64-7
    TI-16 is a peptide that targets β-amyloid (Aβ) protein. TI-16 can cross the blood-brain barrier. TI-16 can increase the concentration of intracellular free CaM, thereby restoring calcium ion homeostasis and reducing Aβ toxicity. TI-16 can reduce the deposition of Aβ in the brain, improve neuronal pathology, inhibit cell apoptosis, and improve cognitive function in mice. TI-16 is commonly used in the study of Alzheimer's disease.
    TI-16
  • HY-P11227
    Compound 19A8.8 98%
    Compound 19A8.8 is a cyclic peptide derived from a CD36 protein fragment. Compound 19A8.8 inhibits the TGF-β/Smad3 signaling pathway by suppressing the interaction between TSP1 and CD36. Compound 19A8.8 has no obvious cytotoxicity. Compound 19A8.8 can be used for research on colon injury and fibrosis.
    Compound 19A8.8
  • HY-P11243
    EphA4 agonist compound 23
    EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases.
    EphA4 agonist compound 23
  • HY-P11244
    150D4 2866306-73-0
    150D4 is an efficient, selective, and blood-brain barrier penetrable EphA4 agonist. 150D4 has excitatory activity and neuroprotective effects. 150D4 can be used for research on neurological conditions.
    150D4
  • HY-P11249
    Mr1.1[S4Dap, C16Pen]
    Mr1.1[S4Dap, C16Pen] is a highly active and selective nAChR (human α9α10 nAChR IC50 = 4.0 nM, rat α9α10 nAChR IC50 = 2.7 nM) inhibitor. Mr1.1[S4Dap, C16Pen] can significantly relieve pain and has significant stability. Mr1.1[S4Dap, C16Pen] can be used for the study of neuropathic pain.
    Mr1.1[S4Dap, C16Pen]
  • HY-P11263
    AVLX-144 1413933-25-1 98%
    AVLX-144 is a highly potent inhibitor of postsynaptic density protein 95 (PSD-95). AVLX-144 can be used as a template to develop imaging probes for postsynaptic density (PSD) molecules, and can be labeled with fluorine-18 (¹⁸F) or tritium (³H) to visualize PSD-95 in vivo. AVLX-144 can be utilized for the study of Parkinson's disease.
    AVLX-144
  • HY-P11284
    TGN 1312882-14-6 98%
    TGN, a 12-amino acid ligand, is a BBB-penetrating peptide. TGN can be used as a drug delivery vehicle for Alzheimer's disease research.
    TGN
  • HY-P11299
    EBNA-1 (386–405 aa) 3082858-70-3
    EBNA-1 (386-405 aa) is a cross-reactive viral antigen peptide. EBNA-1 (386-405 aa) has a high molecular similarity to GlialCAM (370-389 aa) and it induces the production of cross-reactive antibodies that recognize both EBV antigens and glial cells in the central nervous system, thereby triggering autoimmune responses. EBNA-1 (386-405 aa) can used for Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) research.
    EBNA-1 (386–405 aa)
  • HY-P11301
    C16-pHD108
    C16-pHD108 is a pH-responsive nanopore-forming peptide. C16-pHD108 functions as a macromolecule delivery carrier via endosomal membrane nanoporation. C16-pHD108 is promising for research of cancers and neurodegenerative diseases.
    C16-pHD108
  • HY-P11309
    QL6 peptide 957365-81-0 98%
    QL6 peptide is a self-assembling peptide. QL6 peptide can self-assembles into β-sheets bridging the cavity at neutral pH and improves the inhibitory environment by reducing inflammation and tissue scaring. QL6 peptide can be used for synthesis nanofiber scaffolds for spinal cord injuries (SCI) research.
    QL6 peptide
  • HY-P11312
    [S5K, F6Y, L9mL, M10Mox] neurokinin A (4-10) 2770688-17-8 98.14%
    [S5K, F6Y, L9mL, M10Mox] neurokinin A (4-10) is a neuropeptide A analog and a peptide fragment of EB1002 (HY-P10746). [S5K, F6Y, L9mL, M10Mox] neurokinin A (4-10) is highly selective for mouse tachykinin receptors and human tachykinin receptor NK1R.
    [S5K, F6Y, L9mL, M10Mox] neurokinin A (4-10)
Cat. No. Product Name / Synonyms Application Reactivity